IPH5201

BIOLOGICAL2 trials

Sponsors

Innate Pharma, MedImmune LLC

Conditions

Advanced Solid TumorsIIINon-Small Cell Lung Cancer II

Phase 1

IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors.

CompletedNCT04261075

MedImmune LLCAdvanced Solid Tumors

Start: 2020-03-03End: 2022-06-16Updated: 2022-08-15

Phase 2

A Phase II Multicenter, open label, non-randomized study of neoadjuvant and Adjuvant Treatment with IPH5201 and durvalumab in patients with resectable, early-Stage (II to III) Non-Small Cell Lung Cancer (MATISSE)

RecruitingCTIS2023-507778-42-00

Innate PharmaIII, Non-Small Cell Lung Cancer II

Start: 2023-03-08Target: 69Updated: 2025-09-24

Related Papers

188P IPH5201 as monotherapy or in combination with durvalumab (D) in advanced solid tumours

Immuno-Oncology Technology2022-12-013 citations

190P Combination of IPH5201, a blocking antibody targeting the CD39 immunosuppressive pathway, with durvalumab and chemotherapies: Preclinical rationale

Immuno-Oncology Technology2022-12-012 citations